Literature DB >> 10479502

Interstitial brachytherapy for vaginal recurrences of endometrial carcinoma.

K Tewari1, F Cappuccini, W R Brewster, P J DiSaia, M L Berman, A Manetta, A Puthawala, A M Nisar Syed, M F Kohler.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the efficacy of interstitial brachytherapy in the management of vaginal recurrences of endometrial carcinoma.
METHODS: Thirty patients received interstitial irradiation, with or without external beam radiotherapy. They were followed for a minimum of 5 years or until death.
RESULTS: The median age was 66 years at initial diagnosis of endometrial cancer. FIGO stages included Stage I (n = 18), Stage II (n = 7), and Stage III (n = 5). All patients were treated originally by total abdominal hysterectomy and bilateral salpingo-oophorectomy, with or without lymphadenectomy, and 13 (43%) also received postoperative adjuvant whole pelvis radiotherapy as part of their primary treatment. Vaginal recurrences were diagnosed at a mean interval of 29 months after hysterectomy (range, 3-119 months). No patient had clinical evidence of pelvic sidewall extension or of distant metastatic disease. All patients were treated with interstitial brachytherapy; each implant delivered a mean maximal tumor dose of 25.5 Gy. Eighteen patients (60%) also received external beam radiotherapy (mean dose, 48 Gy) as part of their treatment for vaginal recurrence. Twenty-eight patients (93%) experienced a complete clinical response. Ten patients relapsed in the vagina (n = 5) or at distant sites (n = 5). Eleven patients are dead of disease. From the time of vaginal recurrence, the median overall survival was 60 months and the cause of death adjusted 5-year survival rate was 65%. Major morbidity included radiation proctitis (n = 2), fistula (n = 2), and radiation stricture (n = 1).
CONCLUSION: Interstitial irradiation resulted in favorable local control as well as a 5-year survival rate and morbidity comparable to that reported previously for conventional brachytherapy. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10479502     DOI: 10.1006/gyno.1999.5487

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Treatment for advanced and recurrent endometrial carcinoma: combined modalities.

Authors:  J Alejandro Rauh-Hain; Marcela G Del Carmen
Journal:  Oncologist       Date:  2010-07-21

Review 2.  Vaginal necrosis: A rare late toxicity after radiation therapy.

Authors:  Angela Y Jia; Akila N Viswanathan
Journal:  Gynecol Oncol       Date:  2020-12-07       Impact factor: 5.482

3.  High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report.

Authors:  Mio Nakata; Ken Yoshida; Taiju Shimbo; Nobuhiko Yoshikawa; Hiroto Yoshioka; Akihiro Hori; Chikara Sato; Yasuo Uesugi; Yuhei Kogata; Koji Masui; Naoya Murakami; Tairo Kashihara; Hironori Akiyama; Nikolaos Tselis; Masahide Ohmichi; Keiji Nihei
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

4.  High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina.

Authors:  Sushil Beriwal; Dwight E Heron; Robert Mogus; Robert P Edwards; Joseph L Kelley; Paniti Sukumvanich
Journal:  Radiat Oncol       Date:  2008-02-13       Impact factor: 3.481

5.  Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer.

Authors:  Samuel M Shin; Tamara L Duckworth; Benjamin T Cooper; John P Curtin; Peter B Schiff; J Keith DeWyngaert; Stella C Lymberis
Journal:  Front Oncol       Date:  2015-09-14       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.